Cancer
Lung cancer in Shanghai
上海 肺癌
22 hospitals in Shanghai
Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Shanghai may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 414 papers led
- 394 papers led
- 243 papers led
- 186 papers led
- 88 papers led
- 68 papers led
- 62 papers ledNo open trial led
- 61 papers ledNo open trial led
- 50 papers led
- 49 papers led
- 44 papers ledNo open trial led
- 43 papers ledNo open trial led
- 42 papers ledNo open trial led
- 40 papers ledNo open trial led
- 33 papers ledNo open trial led
- 32 papers ledNo open trial led
- 30 papers ledNo open trial led
- 28 papers ledNo open trial led
- 20 papers led
- 6 papers led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
Lung cancer in every city Shanghai on the disease page, with the national map
open trials on lung cancer with a hospital in Shanghai
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Shanghai as lead sponsor or study site. 147 of them are led by a hospital in Shanghai. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase
- Phase 2/Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07063745
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Wuhan, Xiamen
- RecruitingBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07195695
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07222566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingA Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07227025
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Harbin, Shanghai
- RecruitingSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07227298
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Shanghai, Taizhou, Wuhan
- RecruitingA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07227597
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangmen, Nanchang, Shanghai, Taizhou
- RecruitingStudy of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07231445
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07253142
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Guangzhou, Harbin, Hefei, Nanning, Shanghai, Wuhan, Xinxiang, Xuzhou
- RecruitingA Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07269782
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07288177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07308106
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07309276
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07323056
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingA Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07325136
Age 18 years to Not stated (registered criteria)
Led by Shanghai East Hospital, Tongji UniversityShanghai
- RecruitingFirst in Human Study of SIM0610 in Solid Tumors
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07348211
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang
- RecruitingA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07361510
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shantou
- RecruitingA Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07367529
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan
- RecruitingComparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07398937
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingIBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07408635
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingEfficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07410975
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07416474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai
- RecruitingA Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07416695
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07431827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Urumqi, Wuhan
- RecruitingA Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07434518
Age 18 years to 100 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07472517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07476287
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07489066
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingA Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07502300
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou
- RecruitingElectroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07515027
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingJS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07518160
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDownstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07528066
Age not stated (registered criteria)
Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin
- RecruitingRATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07541521
Age not stated (registered criteria)
Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin
- RecruitingVebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07549061
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07554339
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen
- RecruitingComparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07554846
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase II Study of GC101 in NSCLC
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07560111
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07562581
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSeptum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07564557
Age 18 years to 80 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingEstablishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07565532
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07586202
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin
- RecruitingA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07623356
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingAssociation Between Screening Behaviors and Lung Cancer Spectrum
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07626177
Age not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
- Phase
- Phase 2/Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07642024
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai
- RecruitingA Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07654400
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07668752
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07672223
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai
- RecruitingLabel-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07681245
Age 18 years to 90 years (registered criteria)
Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingSKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07697586
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Phase
- Phase 1/Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07707895
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesNanning, Shanghai
- RecruitingA Study of DS-3939a in Participants With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07739966
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou
- RecruitingOral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
- Phase
- Phase 4
- Started
- 2026-06
- Posted
- Registry
- NCT07754812
Age 70 years to Not stated (registered criteria)
Led by Shanghai Pulmonary Hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai
- RecruitingPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07778316
Age 18 years to 99 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingA Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07802821
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingReal World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07806604
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingOlive Oil Before Lung Cancer Surgery to Prevent Chylothorax
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07807696
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)
- Phase
- Phase 1
- Started
- 2026-09
- Posted
- Registry
- NCT07830342
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07843940
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Harbin, Shanghai
- RecruitingNeoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07863999
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary Hospital; 4 listed hospitals as study sitesShanghai
- RecruitingEffectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07874581
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingReal-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07880353
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingThe Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT05798845
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingSleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT06687408
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou, Shanghai
- RecruitingSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06712316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou
- RecruitingSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06712355
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingThe Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06738160
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06754930
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06758401
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingPost-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06758700
Age 18 years to 75 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06772623
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Nanchang, Nanjing, Shanghai, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06775743
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06780098
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Zhengzhou
- RecruitingA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06780137
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanjing, Shanghai
- RecruitingA Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06792552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang
- RecruitingA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06793215
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan
- RecruitingStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06801834
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingClinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06809764
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou
- RecruitingBiomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT06818149
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06839105
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan
- RecruitingDREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT06846762
Age not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06858813
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingReal World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06862869
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi
- RecruitingA Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT06868485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Shanghai, Tianjin, Wuhan
- RecruitingA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06875310
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
- RecruitingStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06890598
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an
- RecruitingStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06899126
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingA Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06901817
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAnti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06903117
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06903377
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPhase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06927986
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06928389
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSleep Disorders and Tumor Immune Microenvironment
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT06941948
Age 18 years to 70 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingStudy of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06943235
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06954246
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06955988
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingBovine Reinforcement in Stomach, Colorectal and Lung Operation
- Phase
- Phase 3
- Started
- 2025-05
- Posted
- Registry
- NCT06968221
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingTransbronchial MWA for Pulmonary Tumors
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT06969014
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingNeoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06987734
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingA Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07003321
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingRadical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT07003490
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07005102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Wuhan
- RecruitingA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07010263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi
- RecruitingA Study of SKB518 in Patients With Lung Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07019675
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenzhen, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xiangyang, Zhengzhou
- RecruitingA Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07056556
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07058519
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingPhase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07063329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou
- RecruitingDZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07070440
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy of GV20-0251 in Participants With Solid Tumor Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07070518
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07079475
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin
- RecruitingA Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07091305
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingPerioperative Immunotherapy for Resectable Limited-Stage SCLC
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT07109401
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07109531
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07111520
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou
- RecruitingSunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT07117890
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingThoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07134660
Age 18 years to 80 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingSleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07135856
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07144280
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07154706
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07155174
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07155187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Nanchang, Shanghai, Urumqi
- RecruitingA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07164170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- RecruitingHC010 in First-line PD-L1 Positive Advanced NSCLC Patients
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07169552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07169994
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang
- RecruitingA Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07171606
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07174908
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07181473
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingStudy Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07189455
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07190248
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingStudy on the Mechanism of Acquired Resistance of Entrectinib
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT07199959
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07206498
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesFuzhou, Shanghai, Tianjin
- RecruitingA Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07217301
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou
- RecruitingA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07218146
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07226999
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingA Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07229599
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSafety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules
- Phase
- N/A
- Started
- 2025-11
- Posted
- Registry
- NCT07232433
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07232849
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSynthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07243873
Age 18 years to 85 years (registered criteria)
Led by Shanghai Pulmonary Hospital; 3 listed hospitals as study sitesNanchang, Shanghai, Zunyi
- RecruitingA Study of Ivonescimab in First-Line ES-SCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07245446
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai, Xi'an
- RecruitingKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07252739
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Nanchang, Nanjing, Shanghai
- RecruitingExploratory Trial of Navigational Bronchoscopy-Guided Cryoablation in Lung Cancer Treatment
- Phase
- N/A
- Started
- 2025-11
- Posted
- Registry
- NCT07301411
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07361237
Age 18 years to 75 years (registered criteria)
Led by Shanghai East Hospital, Tongji UniversityShanghai
- RecruitingA Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07362459
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07376707
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingEffectiveness of Perioperative Percutaneous Acupuncture on Postoperative Sleep Disturbances and Chronic Pain in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT07662733
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingTargeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07742332
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingStation 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLC
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07801430
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingCarbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT05613452
Age 18 years to 80 years (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingToripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06127303
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest Hospital; 2 listed hospitals as study sitesShanghai
- RecruitingA Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06179069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06203210
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingWBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
- Phase
- Phase 1/Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06243003
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingNeoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06256237
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingIrinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT06258642
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingNeoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06269211
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 1 listed hospital as study siteGuangzhou, Shanghai
- RecruitingDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06283719
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06306456
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Hefei, Nanjing, Shanghai, Taizhou, Zhengzhou
- RecruitingCarbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06311981
Age 75 years to Not stated (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase
- Phase 3
- Started
- 2024-04
- Posted
- Registry
- NCT06312137
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Taizhou, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06345729
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study of GC203 TIL in Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06375187
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06403735
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHarbin, Kunming, Nanchang, Shanghai
- RecruitingJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06416410
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou
- RecruitingPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Phase
- Phase 3
- Started
- 2024-06
- Posted
- Registry
- NCT06422143
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Study of FZ-AD005 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06424665
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Hangzhou, Shanghai
- RecruitingA Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06430437
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06437509
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
- Phase
- Phase 3
- Started
- 2024-09
- Posted
- Registry
- NCT06437977
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06452277
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingA Phase Ib Study of GC101 in NSCLC
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06473961
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingImproving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
- Phase
- N/A
- Started
- 2024-03
- Posted
- Registry
- NCT06483295
Age 18 years to 80 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06496490
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi
- RecruitingCranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06501391
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingTransthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer
- Phase
- N/A
- Started
- 2024-01
- Posted
- Registry
- NCT06503744
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06505824
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDifferentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
- Phase
- Not given
- Started
- 2024-06
- Posted
- Registry
- NCT06518655
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Foshan, Guangzhou, Shanghai, Wuhan
- RecruitingAdjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06528847
Age 18 years to 74 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingPrimary Tumor Resection for M1a Stage Lung Cancer
- Phase
- Not given
- Started
- 2024-04
- Posted
- Registry
- NCT06547710
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Phase
- Phase 3
- Started
- 2024-10
- Posted
- Registry
- NCT06561386
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang
- RecruitingBefotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
- Phase
- Phase 4
- Started
- 2024-05
- Posted
- Registry
- NCT06561620
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06564324
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingStudy of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06567015
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin
- RecruitingTransthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
- Phase
- N/A
- Started
- 2024-09
- Posted
- Registry
- NCT06572540
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Shanghai, Zhengzhou
- RecruitingSubcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06598306
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai
- RecruitingA Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06612840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThe Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
- Phase
- Not given
- Started
- 2024-07
- Posted
- Registry
- NCT06623487
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Phase 2 Clinical Study of ABSK061 and ABSK043
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06632262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Jinan, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingAI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06632886
Age 18 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingSegmentectomy for Solid-dominant Lung Cancer
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06634966
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSelective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
- Phase
- N/A
- Started
- 2024-05
- Posted
- Registry
- NCT06634979
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingHigh-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06652048
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingPerioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06659042
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingIntrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06663306
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06668103
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangchun, Harbin, Shanghai, Wuhan
- RecruitingArtificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06684418
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEfficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06698965
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingClinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT06739031
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingLymph Node Pathologic Grading Strategy
- Phase
- Not given
- Started
- 2024-04
- Posted
- Registry
- NCT06745830
Age not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingDisitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06749860
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingAn Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06749886
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingNeoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06755684
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Recruiting68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06756217
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study on the Efficacy of Atezolizumab Combined with Chemotherapy
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06780826
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingTrop2-targeted immunoPET Imaging of Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2024-12
- Posted
- Registry
- NCT06851663
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingClinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT07026110
Age 18 years to 80 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingNoninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT07399210
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingCarbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT07433283
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou
- RecruitingAn Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT07444281
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSegmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
- Phase
- Phase 3
- Started
- 2023-02
- Posted
- Registry
- NCT05717803
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingInduction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05766800
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2023-04
- Posted
- Registry
- NCT05786924
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Jinan, Shanghai, Suzhou
- RecruitingA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05789082
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Harbin, Shanghai
- RecruitingArmatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-01
- Posted
- Registry
- NCT05800223
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingExploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment
- Phase
- Not given
- Started
- 2023-05
- Posted
- Registry
- NCT05857800
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT05882058
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Hangzhou, Jinan, Nanchang, Shanghai
- RecruitingA Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05913089
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang
- RecruitingA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05920356
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingExploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2023-10
- Posted
- Registry
- NCT05965024
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingExploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT05965557
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT05987826
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06010329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingSublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
- Phase
- Phase 3
- Started
- 2023-03
- Posted
- Registry
- NCT06031181
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAdjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
- Phase
- Phase 3
- Started
- 2023-03
- Posted
- Registry
- NCT06041776
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- RecruitingTransbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer
- Phase
- N/A
- Started
- 2023-10
- Posted
- Registry
- NCT06052098
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT06080776
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06095583
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou
- RecruitingA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06119581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang
- RecruitingA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-11
- Posted
- Registry
- NCT06131840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06147570
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06170788
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou
- RecruitingRandomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06205927
Age 18 years to 80 years (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingExploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT06216782
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingDZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
- Phase
- Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT06276283
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingVebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
- Phase
- Phase 1/Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT06343064
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPredicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT06358222
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingSurgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
- Phase
- Not given
- Started
- 2023-08
- Posted
- Registry
- NCT06534489
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingGlycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
- Phase
- Not given
- Started
- 2023-10
- Posted
- Registry
- NCT06730503
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingSmall Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2023-01
- Posted
- Registry
- NCT07070011
Age 45 years to 80 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingPatient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT07328945
Age 18 years to 80 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)
- Phase
- N/A
- Started
- 2022-02
- Posted
- Registry
- NCT03786003
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
- Phase
- N/A
- Started
- 2022-02
- Posted
- Registry
- NCT04527419
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingNeoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT04728724
Age 18 years to 75 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2022-03
- Posted
- Registry
- NCT04928846
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingPreoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2022-10
- Posted
- Registry
- NCT04973293
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05168566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Posted
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingFirst-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
- Phase
- Phase 1/Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT05271916
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05288205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
- RecruitingPhase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
- Phase
- Phase 3
- Started
- 2022-06
- Posted
- Registry
- NCT05382728
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Shanghai
- RecruitingA Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05482568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai
- RecruitingA Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
- Phase
- Phase 3
- Started
- 2022-12
- Posted
- Registry
- NCT05487391
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingChina Lung Cancer Screening (CLUS) Study Version 3.0
- Phase
- N/A
- Started
- 2022-01
- Posted
- Registry
- NCT05494021
Age 45 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05498428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Harbin, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai
- RecruitingNeoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
- Phase
- Phase 2
- Started
- 2022-02
- Posted
- Registry
- NCT05503667
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingAdjuvant Treatment Based on MRD for EGFR Mutant NSCLC
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05536505
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingInduction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT07632365
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase
- Phase 1
- Started
- 2021-07
- Posted
- Registry
- NCT04886804
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
- RecruitingA Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules
- Phase
- Phase 2
- Started
- 2021-01
- Posted
- Registry
- NCT04905056
Age 18 years to 85 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Phase
- Phase 1
- Started
- 2021-08
- Posted
- Registry
- NCT04913285
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHarbin, Linyi, Shanghai
- RecruitingStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT04930432
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05024214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Shanghai, Shenyang, Taiyuan, Tianjin, Zhengzhou, Zhuhai
- RecruitingEfficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
- Phase
- Phase 2
- Started
- 2021-03
- Posted
- Registry
- NCT05053802
Age 18 years to 79 years (registered criteria)
Led by Shanghai Pulmonary Hospital; 5 listed hospitals as study sitesShanghai
- RecruitingFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 1/Phase 2
- Started
- 2021-10
- Posted
- Registry
- NCT05099172
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Taizhou
- RecruitingPhase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
- Phase
- N/A
- Started
- 2021-01
- Posted
- Registry
- NCT05552846
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingNeuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
- Phase
- Not given
- Started
- 2021-01
- Posted
- Registry
- NCT06369181
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
- Phase
- Phase 3
- Started
- 2020-07
- Posted
- Registry
- NCT04316364
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Zhengzhou
- RecruitingPD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
- Phase
- Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04539977
Age 18 years to 75 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Phase
- Phase 2/Phase 3
- Started
- 2020-12
- Posted
- Registry
- NCT04613596
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-07
- Posted
- Registry
- NCT04270591
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou
- RecruitingSegmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
- Phase
- N/A
- Started
- 2019-10
- Posted
- Registry
- NCT04937283
Age 20 years to 79 years (registered criteria)
Led by Shanghai Pulmonary Hospital; 8 listed hospitals as study sitesHangzhou, Hefei, Nantong, Ningbo, Shanghai, Xuzhou
- RecruitingMolecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT05701787
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingComparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
- Phase
- Not given
- Started
- 2019-08
- Posted
- Registry
- NCT05838053
Age 20 years to 79 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingStudy of High Efficient Killing Cell Therapy for Advanced NSCLC
- Phase
- Phase 1
- Started
- 2017-09
- Posted
- Registry
- NCT03193567
Age 18 years to 70 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingSurgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
- Phase
- Phase 2
- Started
- 2017-09
- Posted
- Registry
- NCT03351842
Age 19 years to 70 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingStereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
- Phase
- Phase 2
- Started
- 2017-08
- Posted
- Registry
- NCT03392233
Age 18 years to 85 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingIntegrative Analysis of Large-cell Lung Cancer
- Phase
- Not given
- Started
- 2016-01
- Posted
- Registry
- NCT02917369
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai
- RecruitingAnalysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2016-07
- Posted
- Registry
- NCT04977791
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingMolecular Analysis and Treatment Options of SCLC
- Phase
- Not given
- Started
- 2016-01
- Posted
- Registry
- NCT05945745
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingAssociation of Psychological Distress in Patients With Lung Cancer
- Phase
- Not given
- Started
- 2016-01
- Posted
- Registry
- NCT06218901
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2008-01
- Posted
- Registry
- NCT02889666
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai
- Not yet recruitingA Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2027-12
- Posted
- Registry
- NCT05745740
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07014878
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingClinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
- Phase
- Phase 4
- Started
- 2026-01
- Posted
- Registry
- NCT07358520
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Xuzhou
- Not yet recruitingPhase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07360132
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
- Phase
- Not given
- Started
- 2026-02
- Posted
- Registry
- NCT07375979
Age 40 years to 74 years (registered criteria)
Led by Shanghai Pulmonary Hospital; 5 listed hospitals as study sitesChangchun, Kunming, Shanghai, Shenyang, Zhengzhou
- Not yet recruitingPhase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07383116
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07414927
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
- Phase
- Phase 4
- Started
- 2026-04
- Posted
- Registry
- NCT07469488
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingStudy on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07493980
Age 18 years to 80 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingCombining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07517640
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingA Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07538973
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesQingdao, Shanghai
- Not yet recruitingA Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07550842
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangzhou, Harbin, Shanghai, Shenyang, Taizhou, Wuhan, Zhengzhou
- Not yet recruitingPhase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07558200
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07583771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingApplication of Electromagnetic Navigation System in Pulmonary Nodule Localization
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07595120
Age 18 years to 80 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingSegmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07698990
Age 18 years to 80 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingHSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07699757
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingThe Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07704645
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Phase 2 Study of ABSK043 Combined With Osimertinib
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07710612
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Taiyuan, Wuhan
- Not yet recruitingJS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC
- Phase
- N/A
- Started
- 2026-07
- Posted
- Registry
- NCT07714304
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai
- Not yet recruitingSafety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07745790
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingThe Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07780578
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruiting5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies
- Phase
- N/A
- Started
- 2026-11
- Posted
- Registry
- NCT07830095
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingA Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07831863
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingPhase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07874282
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingPulsed Field Ablation for the Treatment of Malignant Lung Tumors
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07889297
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingAdebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07890636
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-12
- Posted
- Registry
- NCT07896005
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai
- Not yet recruitingASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07897188
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingStudy of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-11
- Posted
- Registry
- NCT07912268
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Fuzhou, Harbin, Nanchang, Shanghai
- Not yet recruitingNeoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06688656
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingNeoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06837948
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingA Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07036185
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingSerplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07064876
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingA Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07086326
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai, Xi'an
- Not yet recruitingToripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07097948
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingA Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07101627
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary Hospital; 1 listed hospital as study siteNanjing, Shanghai
- Not yet recruitingNovel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07135297
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest Hospital; 4 listed hospitals as study sitesBeijing, Nanjing, Ningbo, Shanghai, Zhengzhou
- Not yet recruitingVebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07156604
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingSegmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07169903
Age 20 years to 79 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingReal-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
- Phase
- Not given
- Started
- 2025-10
- Posted
- Registry
- NCT07199010
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingThe Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07277088
Age 18 years to 80 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingSafety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06332950
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingEfficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
- Phase
- N/A
- Started
- 2024-06
- Posted
- Registry
- NCT06453889
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingTrametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06456138
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingCryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer
- Phase
- N/A
- Started
- 2024-09
- Posted
- Registry
- NCT06580665
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesNanchang, Shanghai, Wenzhou, Wuhan
- Not yet recruitingA Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06585644
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingTP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
- Phase
- Early phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06619886
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- Not yet recruitingEfficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06620822
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingA Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06690671
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingA Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06724263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingThe Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-08
- Posted
- Registry
- NCT05496166
Age 18 years to 70 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingYK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05767892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05990127
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
- Not yet recruitingStudy of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
- Phase
- Phase 1
- Started
- 2023-09
- Posted
- Registry
- NCT06015568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBengbu, Changsha, Shanghai
- Not yet recruitingWedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06102161
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingPerioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06109402
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Enrolling by invitationPerioperative Treatment Outcomes of Early NSCLC
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06610240
Age not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Enrolling by invitationReal-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06962449
Age not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Enrolling by invitationThe Effect of Semi-recumbent Position on Hypoxemia After Lung Segment/Lobe Surgery
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT07060625
Age 18 years to 85 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Enrolling by invitationEfficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT04762459
Age 18 years to 130 years (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Shanghai
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Cancer Hospital, Fudan University | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Changhai Hospital海军军医大学第一附属医院(长海医院) | 2 | 221 open | 19 | 315 open | 201 open | 8812 open | 101 open | 7 | none | 2 | none | 1 | 1 | 0 | none | none | none | none | none | 9 | none | none | none | none | none | none | 01 open | none | none | none | none | 4 | 1 | 7 | none | 1 | none | 2 | none | none | none | none | none | none | 1 | none | 1 | none | none | none | 1 | none | 0 | 0 | 1 | none | 0 | none | none | none | none | |
| Changzheng Hospital海军军医大学第二附属医院(长征医院) | none | 3 | 151 open | 171 open | 40 | 41 open | none | 10 | none | none | 5 | 16 | 4 | 0 | 2 | 262 open | none | none | none | 6 | none | none | none | 1 | none | none | none | none | none | none | none | 5 | none | 8 | 1 | none | none | 2 | none | 0 | none | none | none | none | 1 | none | 5 | none | none | 2 | 1 | none | none | none | none | none | 1 | none | none | none | none | |
| Child Health Hospital | none | none | none | none | none | none | 26 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 8 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children Hospital, Fudan University | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children's Hospital of Fudan University复旦大学附属儿科医院 | none | none | none | none | none | none | none | 11 | 5 | 0 | 0 | 4 | none | 11 | 1 | none | 0 | none | 0 | 5 | 01 open | none | 1 | none | none | none | none | 1 | 2 | none | 213 open | 5 | 372 open | 3 | 1 | 0 | none | none | none | none | 3 | 11 open | 0 | 2 | 1 | 0 | 2 | 1 | none | 1 | none | 1 | 0 | 4 | 2 | none | 0 | none | 1 | 0 | none | |
| Dahua Hospital | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| East Hospital上海市东方医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Eastern Hepatobiliary Surgery Hospital海军军医大学第三附属医院(东方肝胆外科医院) | none | none | 2144 open | 6 | none | 7 | none | none | none | none | none | 4 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | |
| Eye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院 | 324 open | none | none | none | none | none | none | none | none | 63 open | 0 | none | none | 51 open | none | none | none | none | none | 161 open | none | none | none | none | none | none | none | none | none | none | none | none | 17 | none | none | 0 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | |
| Fengxian District Central Hospital上海市奉贤区中心医院 | none | 3 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fifth People's Hospital of Fudan University复旦大学附属上海市第五人民医院 | none | none | none | none | none | 2 | none | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Naval Medical University | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Rehabilitation Hospital, Tongji University上海市第一康复医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院 | 381 open | 328 open | 542 open | 8817 open | 24331 open | 21211 open | 39090 open | 15 | none | none | 3 | 6 | 0 | none | 4 | none | 0 | none | none | 3318 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Gongli Hospital上海市浦东新区公利医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangming Traditional Chinese Medicine Hospital上海市浦东新区光明中医医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Gynecology Hospital, Fudan University复旦大学附属妇产科医院 | none | none | none | none | none | none | 17 | none | none | none | none | 0 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Health Sciences Affiliated Zhoupu Hospital上海市浦东新区周浦医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Huadong Hospital, Fudan University复旦大学附属华东医院 | none | 11 open | none | 41 open | 42 | 111 open | none | none | none | none | none | 0 | none | none | none | none | none | none | 0 | 6 | none | none | none | none | none | none | none | none | 2 | none | none | 14 | none | none | none | none | none | 0 | none | 0 | none | none | none | none | 24 | none | 1 | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | |
| Huashan Hospital复旦大学附属华山医院 | none | 12 | 621 open | 226 open | 62 | 191 open | 261 open | 1226 open | none | none | 4 | 2 | 0 | 1 | 0 | 5 | none | none | none | 351 open | none | 1 | none | none | none | 231 open | 0 | 314 open | 17 | none | none | 5 | 3 | none | 1 | none | none | 7 | none | 10 | 11 | none | 1 | 1 | 1 | none | 6 | none | none | none | 0 | 0 | none | none | 2 | 1 | none | none | none | none | none | |
| Infant Hospital上海市第一妇婴保健院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jiading District Anting Hospital上海市嘉定区安亭医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jiahui International Hospital上海嘉会国际医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jing'an District Centre Hospital上海市静安区中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jinshan Hospital, Fudan University复旦大学附属金山医院 | none | none | none | none | none | none | none | none | none | none | none | 5 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Longhua Hospital上海中医药大学附属龙华医院 | none | 7 | 11 | 13 | 44 | none | 36 | none | none | none | 1 | 4 | none | 1 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 51 open | none | 2 | none | none | none | 1 | none | none | none | none | none | none | none | none | 1 | none | none | none | 2 | 0 | none | none | none | none | 1 | none | none | none | none | |
| Minhang Hospital上海市闵行区中心医院 | none | none | none | 9 | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Putuo Hospital上海市普陀区中心医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Renji Hospital上海交通大学医学院附属仁济医院 | 22 open | 81 open | 1045 open | 655 open | 883 open | 1037 open | 7620 open | 251 open | 3 | 1 | 1 | 3 | 10 | 2 | none | 242 open | none | none | 3 | 232 open | none | none | 1 | none | none | 111 open | 2 | 31 open | none | none | 3 | 11 | 10 | 0 | 2 | 0 | none | 0 | none | 3 | none | 1 | none | 0 | 2 | none | 6 | none | none | none | 171 open | 5 | none | none | none | 2 | none | none | none | none | none | |
| Ruijin Hospital上海交通大学医学院附属瑞金医院 | none | 221 open | 353 open | 9613 open | 6811 open | 11418 open | 11518 open | 14 | none | none | none | 131 open | 2 | 2 | 0 | 22 | 114 open | none | 2 | 9755 open | 0 | 5 | none | 0 | none | none | none | none | 2 | none | none | 594 open | 2 | 1 | 1 | none | none | 0 | 2 | 2 | 0 | 3 | none | none | none | 1 | 42 open | none | none | none | 0 | none | none | none | none | none | 2 | none | none | none | none | |
| Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine上海市第七人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Baoshan Luodian Hospital上海市宝山区罗店医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Chest Hospital上海市胸科医院 | none | 4012 open | none | none | 41445 open | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 11 | 4 | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Children's Hospital上海市儿童医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 6 | 1 | none | 1 | none | 1 | none | 4 | 0 | none | none | none | none | none | none | none | none | 1 | none | 10 | 2 | none | none | none | none | none | none | none | none | none | 2 | 0 | 0 | 0 | 0 | none | none | none | none | 2 | none | none | none | none | none | none | none | none | |
| Shanghai Children's Medical Center上海交通大学医学院附属上海儿童医学中心 | none | none | none | none | none | none | none | none | 171 open | none | none | 0 | none | 11 | 0 | none | 81 open | 5 | none | 11 | 0 | none | none | none | 2 | none | none | none | none | none | none | none | 971 open | 2 | none | none | none | none | none | none | 0 | 0 | 0 | 02 open | none | none | 3 | 0 | none | none | none | none | 2 | 2 | 1 | none | none | none | none | none | none | |
| Shanghai East Hospital, Tongji University同济大学附属东方医院 | 1 | 13 | 36 | 37 | 502 open | 12 | 50 | 13 | none | 0 | 1 | 2 | 2 | 2 | 1 | 13 | none | none | none | 7 | none | none | none | none | 1 | none | none | none | none | none | none | 201 open | 11 | none | none | none | none | 4 | none | 11 open | none | none | none | none | none | none | 1 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Eighth People Hospital上海市第八人民医院 | none | none | none | none | none | none | none | none | none | 1 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Electric Power Hospital上海电力医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Fengxian District Central Hospital | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Fourth People's Hospital同济大学附属上海市第四人民医院 | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | 31 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai General Hospital上海市第一人民医院 | 5 | 3 | 361 open | 271 open | 494 open | 357 open | 62 | 13 | none | 1 | 5 | 24 | 2 | 0 | none | 2 | 0 | 0 | none | 118 open | none | 0 | none | none | none | none | none | none | none | none | none | 25 | 4 | none | 1 | 1 | none | 1 | none | 1 | none | none | none | none | none | none | 0 | none | none | none | none | 0 | none | none | none | none | none | 2 | none | none | none | |
| Shanghai Jiading Central Hospital上海市嘉定区中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Mengchao Cancer Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Mental Health Center上海市精神卫生中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Municipal Hospital, Shanghai University of Traditional Chinese Medicine上海市中医医院 | none | none | none | none | 28 | none | none | none | none | none | none | 2 | none | 1 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| Shanghai Ninth People's Hospital上海交通大学医学院附属第九人民医院 | 5 | 4 | none | none | 33 | 11 | 27 | 9 | none | 29 | none | 15 | 1 | 2 | none | none | none | none | none | 221 open | none | 1 | none | none | 1 | none | none | none | none | none | none | 15 | 0 | 2 | none | 0 | none | 4 | none | none | 0 | none | none | 1 | 1 | none | 0 | none | none | 1 | 0 | none | none | 0 | 1 | none | none | 1 | none | none | none | |
| Shanghai Proton and Heavy Ion Center上海市质子重离子医院 | 0 | none | 2 | none | 63 open | 01 open | 13 open | 2 | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Pudong Hospital上海市浦东医院 | none | none | none | none | none | 2 | 10 | 6 | none | 0 | none | 0 | none | none | none | 1 | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Pudong New Area People's Hospital上海市浦东新区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Pulmonary Hospital上海市肺科医院 | none | 5 | none | none | 39443 open | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 71 open | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Putuo District Liqun Hospital上海市普陀区利群医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Sixth People's Hospital上海市第六人民医院 | 3 | 0 | 27 | 21 | 43 | 15 | 43 | 8 | none | none | 0 | 35 | 0 | 4 | 1 | 1 | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | 11 | 2 | none | none | none | none | 2 | none | 4 | none | none | none | 0 | none | 0 | 0 | none | none | 7 | 1 | 1 | none | none | none | none | 0 | none | none | none | none | |
| Shanghai Songjiang District Central Hospital上海市松江区中心医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Stomatological Hospital上海市口腔医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Tenth People's Hospital上海市第十人民医院 | none | 3 | 27 | 21 | 61 | 14 | 44 | 12 | 3 | none | 0 | 21 | 0 | 2 | 0 | 5 | none | none | none | 10 | none | none | none | none | none | none | none | none | none | none | none | 27 | none | none | none | 2 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Tong Ren Hospital上海市同仁医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Xuhui Central Hospital上海徐汇中心医院 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Shibei Hospital上海市静安区市北医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shuguang Hospital上海中医药大学附属曙光医院 | none | none | 20 | none | none | none | none | none | none | none | none | 1 | none | 0 | 0 | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | 2 | none | none | none | 3 | none | none | none | none | none | none | none | none | 3 | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| Tongji Hospital同济大学附属同济医院 | none | 3 | none | 17 | 30 | none | none | 9 | none | none | none | 2 | 1 | 2 | none | 21 open | 01 open | 0 | none | 185 open | none | none | none | none | none | none | none | none | none | none | none | 9 | 2 | none | none | none | none | 2 | none | 0 | none | none | none | none | 0 | none | 0 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | |
| Xinhua Hospital上海交通大学医学院附属新华医院 | none | none | 21 | 24 | 32 | 12 | 28 | 32 | 1 | 5 | none | 4 | 0 | 17 | 0 | 2 | none | none | none | 7 | none | none | none | none | none | none | none | 2 | none | 2 | 9 | 7 | 363 open | 33 | 0 | none | none | 0 | none | 1 | 0 | 1 | 0 | 0 | 0 | 01 open | 2 | 21 open | 1 | 0 | 1 | 0 | 3 | 6 | 4 | none | none | none | none | none | none | |
| Xinshijie Zhongxing Eye Hospital上海新视界中兴眼科医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yangpu Hospital上海市杨浦区中心医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yangzhi Rehabilitation Hospital, Tongji University上海市养志康复医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yueyang Hospital, Shanghai University of Traditional Chinese Medicine上海中医药大学附属岳阳中西医结合医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | none | |
| Zhabei Central Hospital上海市静安区闸北中心医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhongshan Hospital, Fudan University复旦大学附属中山医院 | 3 | 568 open | 40816 open | 1348 open | 1864 open | 779 open | 441 open | 19 | 3 | none | 0 | 5 | 28 | 0 | 2 | 234 open | none | none | none | 142 open | 1 | none | none | none | none | 0 | 4 | 11 open | none | none | none | 10914 open | 30 | none | 0 | 332 open | none | 3 | 1 | 3 | none | none | none | 1 | 2 | none | 4 | none | none | 1 | 0 | none | none | none | 1 | none | 0 | none | none | none | none | |
| Zhongshan-Xuhui Hospital上海市徐汇区中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Shanghai.
- Nasopharyngeal carcinoma 2
- Oesophageal squamous cell carcinoma 221 open
- Hepatocellular carcinoma 19
- Stomach cancer 315 open
- Lung cancer 201 open
- Pancreatic cancer 8812 open
- Breast cancer 101 open
- Glioma 7
- Retinoblastoma 2
- Osteosarcoma 1
- Gastrointestinal stromal tumour 1
- Neuroblastoma 0
- Lymphoma 9
- IgG4-related disease 01 open
- Coronary heart disease 4
- Congenital heart disease 1
- Scoliosis 7
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Behçet disease 1
- IgA nephropathy 1
- Primary biliary cholangitis 1
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 0
- Inherited epidermolysis bullosa 1
- Familial adenomatous polyposis 0
- Oesophageal squamous cell carcinoma 3
- Hepatocellular carcinoma 151 open
- Stomach cancer 171 open
- Lung cancer 40
- Pancreatic cancer 41 open
- Glioma 10
- Chordoma 5
- Osteosarcoma 16
- Gastrointestinal stromal tumour 4
- Neuroblastoma 0
- Ewing sarcoma 2
- Multiple myeloma 262 open
- Lymphoma 6
- Thrombotic thrombocytopenic purpura 1
- Coronary heart disease 5
- Scoliosis 8
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 0
- Behçet disease 1
- IgA nephropathy 5
- Osteogenesis imperfecta 2
- Primary biliary cholangitis 1
- Familial adenomatous polyposis 1
- Glioma 11
- Hepatoblastoma 5
- Retinoblastoma 0
- Chordoma 0
- Osteosarcoma 4
- Neuroblastoma 11
- Ewing sarcoma 1
- B-cell acute lymphoblastic leukaemia 0
- Haemophagocytic lymphohistiocytosis 0
- Lymphoma 5
- Beta thalassaemia 01 open
- Atypical haemolytic uraemic syndrome 1
- Myasthenia gravis 1
- Moyamoya disease 2
- Biliary atresia 213 open
- Coronary heart disease 5
- Congenital heart disease 372 open
- Scoliosis 3
- Anti-NMDA receptor encephalitis 1
- Takayasu arteritis 0
- Spinal muscular atrophy 3
- Fabry disease 11 open
- Pompe disease 0
- Duchenne muscular dystrophy 2
- Behçet disease 1
- Alport syndrome 0
- IgA nephropathy 2
- Gaucher disease 1
- Osteogenesis imperfecta 1
- Primary sclerosing cholangitis 1
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 4
- Inherited epidermolysis bullosa 2
- Familial adenomatous polyposis 0
- Majeed syndrome 1
- NGLY1 deficiency 0
- Nasopharyngeal carcinoma 381 open
- Oesophageal squamous cell carcinoma 328 open
- Hepatocellular carcinoma 542 open
- Stomach cancer 8817 open
- Lung cancer 24331 open
- Pancreatic cancer 21211 open
- Breast cancer 39090 open
- Glioma 15
- Chordoma 3
- Osteosarcoma 6
- Gastrointestinal stromal tumour 0
- Ewing sarcoma 4
- B-cell acute lymphoblastic leukaemia 0
- Lymphoma 3318 open
- Familial adenomatous polyposis 1
- Oesophageal squamous cell carcinoma 11 open
- Stomach cancer 41 open
- Lung cancer 42
- Pancreatic cancer 111 open
- Osteosarcoma 0
- Haemophagocytic lymphohistiocytosis 0
- Lymphoma 6
- Moyamoya disease 2
- Coronary heart disease 14
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 0
- Behçet disease 24
- IgA nephropathy 1
- Congenital diaphragmatic hernia 1
- Oesophageal squamous cell carcinoma 12
- Hepatocellular carcinoma 621 open
- Stomach cancer 226 open
- Lung cancer 62
- Pancreatic cancer 191 open
- Breast cancer 261 open
- Glioma 1226 open
- Chordoma 4
- Osteosarcoma 2
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Ewing sarcoma 0
- Multiple myeloma 5
- Lymphoma 351 open
- Haemophilia A 1
- Neuromyelitis optica spectrum disorder 231 open
- IgG4-related disease 0
- Myasthenia gravis 314 open
- Moyamoya disease 17
- Coronary heart disease 5
- Congenital heart disease 3
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 7
- Amyotrophic lateral sclerosis 10
- Spinal muscular atrophy 11
- Pompe disease 1
- Duchenne muscular dystrophy 1
- Behçet disease 1
- IgA nephropathy 6
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 0
- Inherited epidermolysis bullosa 2
- Hereditary angioedema 1
- Oesophageal squamous cell carcinoma 7
- Hepatocellular carcinoma 11
- Stomach cancer 13
- Lung cancer 44
- Breast cancer 36
- Chordoma 1
- Osteosarcoma 4
- Neuroblastoma 1
- Haemophilia A 1
- Coronary heart disease 51 open
- Scoliosis 2
- Idiopathic pulmonary fibrosis 1
- IgA nephropathy 1
- Primary biliary cholangitis 2
- Primary sclerosing cholangitis 0
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 22 open
- Oesophageal squamous cell carcinoma 81 open
- Hepatocellular carcinoma 1045 open
- Stomach cancer 655 open
- Lung cancer 883 open
- Pancreatic cancer 1037 open
- Breast cancer 7620 open
- Glioma 251 open
- Hepatoblastoma 3
- Retinoblastoma 1
- Chordoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 10
- Neuroblastoma 2
- Multiple myeloma 242 open
- Haemophagocytic lymphohistiocytosis 3
- Lymphoma 232 open
- Atypical haemolytic uraemic syndrome 1
- Neuromyelitis optica spectrum disorder 111 open
- IgG4-related disease 2
- Myasthenia gravis 31 open
- Biliary atresia 3
- Coronary heart disease 11
- Congenital heart disease 10
- Scoliosis 0
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 3
- Fabry disease 1
- Duchenne muscular dystrophy 0
- Behçet disease 2
- IgA nephropathy 6
- Primary biliary cholangitis 171 open
- Primary sclerosing cholangitis 5
- Hereditary angioedema 2
- Oesophageal squamous cell carcinoma 221 open
- Hepatocellular carcinoma 353 open
- Stomach cancer 9613 open
- Lung cancer 6811 open
- Pancreatic cancer 11418 open
- Breast cancer 11518 open
- Glioma 14
- Osteosarcoma 131 open
- Gastrointestinal stromal tumour 2
- Neuroblastoma 2
- Ewing sarcoma 0
- Multiple myeloma 22
- B-cell acute lymphoblastic leukaemia 114 open
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 9755 open
- Beta thalassaemia 0
- Haemophilia A 5
- Thrombotic thrombocytopenic purpura 0
- Moyamoya disease 2
- Coronary heart disease 594 open
- Congenital heart disease 2
- Scoliosis 1
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 0
- Lymphangioleiomyomatosis 2
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 0
- Fabry disease 3
- Alport syndrome 1
- IgA nephropathy 42 open
- Primary biliary cholangitis 0
- Familial adenomatous polyposis 2
- Osteosarcoma 1
- Neuroblastoma 6
- Ewing sarcoma 1
- B-cell acute lymphoblastic leukaemia 1
- Haemophagocytic lymphohistiocytosis 1
- Beta thalassaemia 4
- Haemophilia A 0
- Biliary atresia 1
- Congenital heart disease 10
- Scoliosis 2
- Duchenne muscular dystrophy 2
- Behçet disease 0
- Alport syndrome 0
- IgA nephropathy 0
- Gaucher disease 0
- Congenital diaphragmatic hernia 2
- Hepatoblastoma 171 open
- Osteosarcoma 0
- Neuroblastoma 11
- Ewing sarcoma 0
- B-cell acute lymphoblastic leukaemia 81 open
- Aplastic anaemia 5
- Lymphoma 11
- Beta thalassaemia 0
- Fanconi anaemia 2
- Congenital heart disease 971 open
- Scoliosis 2
- Spinal muscular atrophy 0
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 02 open
- IgA nephropathy 3
- Gaucher disease 0
- Congenital diaphragmatic hernia 2
- Hirschsprung disease 2
- Inherited epidermolysis bullosa 1
- Nasopharyngeal carcinoma 1
- Oesophageal squamous cell carcinoma 13
- Hepatocellular carcinoma 36
- Stomach cancer 37
- Lung cancer 502 open
- Pancreatic cancer 12
- Breast cancer 50
- Glioma 13
- Retinoblastoma 0
- Chordoma 1
- Osteosarcoma 2
- Gastrointestinal stromal tumour 2
- Neuroblastoma 2
- Ewing sarcoma 1
- Multiple myeloma 13
- Lymphoma 7
- Fanconi anaemia 1
- Coronary heart disease 201 open
- Congenital heart disease 11
- Idiopathic pulmonary fibrosis 4
- Amyotrophic lateral sclerosis 11 open
- IgA nephropathy 1
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 5
- Oesophageal squamous cell carcinoma 3
- Hepatocellular carcinoma 361 open
- Stomach cancer 271 open
- Lung cancer 494 open
- Pancreatic cancer 357 open
- Breast cancer 62
- Glioma 13
- Retinoblastoma 1
- Chordoma 5
- Osteosarcoma 24
- Gastrointestinal stromal tumour 2
- Neuroblastoma 0
- Multiple myeloma 2
- B-cell acute lymphoblastic leukaemia 0
- Aplastic anaemia 0
- Lymphoma 118 open
- Haemophilia A 0
- Coronary heart disease 25
- Congenital heart disease 4
- Anti-NMDA receptor encephalitis 1
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- IgA nephropathy 0
- Primary sclerosing cholangitis 0
- Leber hereditary optic neuropathy 2
- Nasopharyngeal carcinoma 5
- Oesophageal squamous cell carcinoma 4
- Lung cancer 33
- Pancreatic cancer 11
- Breast cancer 27
- Glioma 9
- Retinoblastoma 29
- Osteosarcoma 15
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Lymphoma 221 open
- Haemophilia A 1
- Fanconi anaemia 1
- Coronary heart disease 15
- Congenital heart disease 0
- Scoliosis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 4
- Spinal muscular atrophy 0
- Duchenne muscular dystrophy 1
- Behçet disease 1
- IgA nephropathy 0
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 0
- Hirschsprung disease 0
- Inherited epidermolysis bullosa 1
- Leber hereditary optic neuropathy 1
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 0
- Hepatocellular carcinoma 27
- Stomach cancer 21
- Lung cancer 43
- Pancreatic cancer 15
- Breast cancer 43
- Glioma 8
- Chordoma 0
- Osteosarcoma 35
- Gastrointestinal stromal tumour 0
- Neuroblastoma 4
- Ewing sarcoma 1
- Multiple myeloma 1
- Neuromyelitis optica spectrum disorder 2
- Coronary heart disease 11
- Congenital heart disease 2
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 4
- Duchenne muscular dystrophy 0
- Alport syndrome 0
- IgA nephropathy 0
- Osteogenesis imperfecta 7
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 1
- Familial adenomatous polyposis 0
- Oesophageal squamous cell carcinoma 3
- Hepatocellular carcinoma 27
- Stomach cancer 21
- Lung cancer 61
- Pancreatic cancer 14
- Breast cancer 44
- Glioma 12
- Hepatoblastoma 3
- Chordoma 0
- Osteosarcoma 21
- Gastrointestinal stromal tumour 0
- Neuroblastoma 2
- Ewing sarcoma 0
- Multiple myeloma 5
- Lymphoma 10
- Coronary heart disease 27
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 2
- Oesophageal squamous cell carcinoma 3
- Stomach cancer 17
- Lung cancer 30
- Glioma 9
- Osteosarcoma 2
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Multiple myeloma 21 open
- B-cell acute lymphoblastic leukaemia 01 open
- Aplastic anaemia 0
- Lymphoma 185 open
- Coronary heart disease 9
- Congenital heart disease 2
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 0
- Behçet disease 0
- IgA nephropathy 0
- Primary sclerosing cholangitis 0
- Hepatocellular carcinoma 21
- Stomach cancer 24
- Lung cancer 32
- Pancreatic cancer 12
- Breast cancer 28
- Glioma 32
- Hepatoblastoma 1
- Retinoblastoma 5
- Osteosarcoma 4
- Gastrointestinal stromal tumour 0
- Neuroblastoma 17
- Ewing sarcoma 0
- Multiple myeloma 2
- Lymphoma 7
- Myasthenia gravis 2
- Wilson disease 2
- Biliary atresia 9
- Coronary heart disease 7
- Congenital heart disease 363 open
- Scoliosis 33
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 0
- Fabry disease 1
- Pompe disease 0
- Duchenne muscular dystrophy 0
- Behçet disease 0
- Alport syndrome 01 open
- IgA nephropathy 2
- Gaucher disease 21 open
- Niemann–Pick disease type C 1
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 3
- Hirschsprung disease 6
- Inherited epidermolysis bullosa 4
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 568 open
- Hepatocellular carcinoma 40816 open
- Stomach cancer 1348 open
- Lung cancer 1864 open
- Pancreatic cancer 779 open
- Breast cancer 441 open
- Glioma 19
- Hepatoblastoma 3
- Chordoma 0
- Osteosarcoma 5
- Gastrointestinal stromal tumour 28
- Neuroblastoma 0
- Ewing sarcoma 2
- Multiple myeloma 234 open
- Lymphoma 142 open
- Beta thalassaemia 1
- Neuromyelitis optica spectrum disorder 0
- IgG4-related disease 4
- Myasthenia gravis 11 open
- Coronary heart disease 10914 open
- Congenital heart disease 30
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 332 open
- Idiopathic pulmonary fibrosis 3
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 3
- Duchenne muscular dystrophy 1
- Behçet disease 2
- IgA nephropathy 4
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 0
- Inherited epidermolysis bullosa 1
- Familial adenomatous polyposis 0
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lung cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Shanghai on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.